Top Markets
Coin of the day
Upstream Bio, Inc. Upstream Bio, Inc.

Upstream Bio, Inc.

UPB
Rank in Stocks #15300
Upstream Bio, Inc. is a biotechnology company in the clinical development... Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Share Price
$6.64
Last synced: 2026-08-31
Market Cap
$361.08M
Change (1 day)
-0.82%
Change (1 year)
-61.27%
Country
US
Trade Upstream Bio, Inc. (UPB)

Category

Revenue for Upstream Bio, Inc. (UPB)
Revenue in Sep 2026 TTM: 0
According to Upstream Bio, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Upstream Bio, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
$15.74B -
AU
$2.23B -
US
- -
CH